News
A recent study reveals that a novel postbiotic supplement, Pet Immune, significantly alleviates itching and enhances skin and ...
23h
Clinical Trials Arena on MSNLEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trialThe trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...
Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...
Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.
Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...
11d
Health on MSNSpongiotic Dermatitis: Symptoms, Causes, and How To Treat ItSpongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...
Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.
Atopic dermatitis and contact dermatitis may both have certain triggers that set off your flares. If you can avoid your triggers, you may be able to calm skin rashes or even prevent them.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results